Ex vivo generation of genetically modified dendritic cells for immunotherapy: Implications of lymphocyte contamination

Gene Therapy

Volumn 12, Issue 3, 2005, Pages 259-271

  Chinnasamy, N ^a   Treisman, J S ^a   Oaks, M K ^a   Hanson Jr , J P ^a   Chinnasamy, D ^a  

^a ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Immunotherapy; Lentiviral vectors

Indexed keywords

BETA GALACTOSIDASE; DENDRITIC CELL VACCINE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; PLASMID VECTOR; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL ISOLATION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; DRUG CONTAMINATION; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MONOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOBLAST; T LYMPHOCYTE;

ADOPTIVE TRANSFER; CANCER VACCINES; DENDRITIC CELLS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; LYMPHOCYTES; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13544254596     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302407     Document Type: Article

References (59)

1. Banchereau J. Dendritic cells: therapeutic potentials. Transfus Sci 1997; 18: 313-326.
2. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53: 275-306.
3. Holtl L et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161: 777-782.
4. Nestle FO et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 328-332.
5. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183 317-322.
6. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561.
7. Foley R, Tozer R, Wan Y. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine. Transfus Med Rev 2001; 15: 292-304.
8. + T cells from HIV-1-infected individuals. J Immunol 2000; 165: 6620-6626.
9. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001; 22: 102-107.
10. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11: 797-806.
11. Weissman D et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000; 165: 4710-4717.
12. zum Buschenfelde CM et al. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 2001; 167: 1712-1719.
13. Bender A et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-135.
14. Romani N et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137-151.
15. + blood progenitors for anticancer therapy. Exp Hematol 1995; 23: 1463-1471.
16. Banchereau J et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-6458.
17. Suen Y et al. Comparison of monocyte enrichment by immunomagnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001; 3: 365-375.
18. Thurner B et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223: 1-15.
19. + starting populations. J Hematother Stem Cell Res 2003; 12 289-299.
20. + T cells. J Immunol 1999; 162: 5287-5298.
21. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000; 164: 3095-3101.
22. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997; 185: 2133-2141.
23. Loyer V et al. The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 1999; 163: 6462-6467.
24. Ritchie DS et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods 2000; 246: 109-117.
25. Gruber A et al. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 2000; 96: 1327-1333.
26. Re F et al. Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humans. Exp Hematol 2004; 32: 210-217.
27. Morris JC et al. Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood 2004; 103: 492-499.
28. Rosenzweig M et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951-1959.
29. Gambotto A et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Therapy 2000; 7: 2036-2040.
30. Stripecke R et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Therapy 1999; 6: 1305-1312.
31. Larregina AT et al. Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood 2004; 103: 811-819.
32. Arthur JF et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
33. Lundqvist A et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2002; 25: 445-454.
34. Chinnasamy N et al. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum Gene Ther 2000; 11: 1901-1909.
35. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97: 114-121.
36. Schroers R et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 2000; 1: 171-179.
37. Rouas R et al. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther 2002; 9: 715-724.
38. Koya RC et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 2003; 26: 451-460.
39. Grigera PR et al. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. J Virol 1996; 70: 8492-8501.
40. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
41. Lee CK, Gimeno R, Levy DE. Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes. J Exp Med 1999; 190: 1451-1464.
42. + cell line. Virology 2002; 300: 160-169.
43. + lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc Natl Acad Sci USA 1995; 92: 11225-11229.
44. Leverkus M et al. MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways. Int Immunol 2003; 15: 993-1006.
45. + T cells. Nature 1995; 376: 181-184.
46. Kiener PA et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185: 1511-1516.
47. Rothstein TL et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163-165.
48. +, class II MHC-restricted cytotoxic T cells. Immunology 1990; 71: 208-212.
49. Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-223.
50. Kagi D et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265 528-530.
51. den Boer AT et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 2001; 167: 2522-2528.
52. Dhodapkar MV et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
53. Chiriva-Internati M et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003; 102: 3100-3107.
54. Liu Y et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 2001; 8: 948-957.
55. Valmori D et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 2000; 164: 1125-1131.
56. Hemmer B et al. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 1998; 160: 3631-3636.
57. Misko IS et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci USA 1999; 96: 2279-2284.
58. Bhattachary R et al. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats. Int Immunopharmacol 2002; 2: 783-796.
59. Chinnasamy D et al. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.